Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114728) titled 'ZG005 combination hydrochloride gilteritinib tablets in patients with relapsed or refractory lymphoma: a multicentre, open-label, dose-exploration and dose-expansion phase I/II clinical study' on Dec. 17, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Affiliated Hospital of Zhejiang University School of Medicine
Condition:
Classical Hodgkin lymphoma
mediastinal large B-cell lymphoma
extranodal NK/T-cell lymphoma
Intervention:
Part1-Option B:ZG005 20 mg/kg Q3w GDC-0994 100 mg Bid (D1-D7, CnD1-D14)
Part-1-Option A:ZG005 20 mg/kg Q3w giredestrant 100 mg bid (D1 to end...